Join Growin Stock Community!

Xbiotech inc.XBIT.US Overview

US StockHealthcare
(No presentation for XBIT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

XBIT AI Insights

XBIT Overall Performance

XBIT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

XBIT Recent Performance

2.65%

Xbiotech inc.

0.05%

Avg of Sector

-0.31%

S&P500

XBIT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

XBIT Key Information

XBIT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

XBIT Profile

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Price of XBIT

XBIT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

XBIT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.96
PE Ratio (TTM)
-
Forward PE
19.33
PS Ratio (TTM)
12.23
PB Ratio
0.43
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.96
PE Ratio (TTM)
-
Forward PE
19.33
PS Ratio (TTM)
12.23
PB Ratio
0.43
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is XBIT's latest earnings report released?

    The most recent financial report for Xbiotech inc. (XBIT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating XBIT's short-term business performance and financial health. For the latest updates on XBIT's earnings releases, visit this page regularly.

  • How much cash does XBIT have?

    At the end of the period, Xbiotech inc. (XBIT) held Total Cash and Cash Equivalents of 147.37M, accounting for 0.85 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is XBIT's EPS continuing to grow?

    According to the past four quarterly reports, Xbiotech inc. (XBIT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of XBIT?

    Xbiotech inc. (XBIT)'s Free Cash Flow (FCF) for the period is -4.37M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 29.34% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of XBIT?

    The latest valuation data shows Xbiotech inc. (XBIT) has a Price-To-Earnings (PE) ratio of -2.9 and a Price/Earnings-To-Growth (PEG) ratio of -0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.